Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.
Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.
复制标题
DOI：
10.3802/jgo.2023.34.e44
复制
发表时间：
2023-07
影响因子：
3.9
通讯作者：
Han Z
中科院分区：
文献类型：
--
作者：
Wang L;Li S;Zhu D;Qin Y;Wang X;Hong Z;Han Z
目的：评价NaB-紫杉醇联合铂类一线化疗方案治疗卵巢癌的疗效和安全性。对2018年7月至2021年12月应用铂联合NaB-紫杉醇作为一线化疗治疗上皮性卵巢癌、输卵管癌或原发性腹膜癌的患者进行回顾性评估。主要结果是无进展生存(PFS)。检查不良事件(AEs)。进行亚组分析。对72例患者(中位年龄54.5岁，范围20.0-79.0岁)进行评估，其中分别接受新辅助治疗12例和初次手术加化疗60例。中位随访期为25.6个月，中位PFS为26.7个月(95%可信区间[CI]=24.0~29.3)个月。在新辅助治疗亚组中，中位PFS为26.7(95%CI=22.9~30.5)个月，而初次手术亚组为30.1(95%CI=23.1~37.1)个月。27名患者接受NaB-紫杉醇联合卡铂治疗，中位PFS为30.3个月(95%CI=不可用[NA]-NA)。最常见的3~4级不良反应包括贫血(15.3%)、白细胞减少(11.1%)、中性粒细胞减少(20.8%)。未发生药物相关过敏反应。NAB-紫杉醇加铂作为OC的一线治疗方案与良好的预后相关，对于OC患者是可以耐受的。过敏性反应是紫杉醇溶剂的主要问题。NAB-紫杉醇联合铂治疗卵巢癌可能是可行的。对使用一线NaB-紫杉醇加铂治疗的卵巢癌患者进行了回顾。72例患者的中位无进展生存期为26.7个月。
To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC). Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed. Seventy-two patients (median age, 54.5 years; range, 20.0–79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0–29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9–30.5) months vs. 30.1 (95% CI=23.1–37.1) months in the primary surgery subgroup. Twenty-seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]–NA) months. The commonest grade 3–4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred. Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC. Hypersensitivity reaction is a major problem with solvent-paclitaxel. Nab-paclitaxel plus platinum might be feasible for ovarian cancer (OC). OC patients used first-line nab-paclitaxel plus platinum were reviewed. The median progression-free survival was 26.7 months in 72 patients.
登录
查看更多内容
影响因子：
1.2
作者：
Lam, Clarissa;Ha, Kristal;Hakam, Ardeshir;Shahzad, Mian M. K.
通讯作者：
Shahzad, Mian M. K.
影响因子：
11.5
作者：
Desai, N;Trieu, V;Soon-Shiong, P
通讯作者：
Soon-Shiong, P
影响因子：
5
作者：
Desai, Neil;Trieu, Vuong;Soon-Shiong, Patrick
通讯作者：
Soon-Shiong, Patrick
影响因子：
4.7
作者：
Coleman RL;Brady WE;McMeekin DS;Rose PG;Soper JT;Lentz SS;Hoffman JS;Shahin MS
通讯作者：
Shahin MS
影响因子：
168.9
作者：
Clamp, Andrew R.;James, Elizabeth C.;Ledermann, Jonathan A.
通讯作者：
Ledermann, Jonathan A.